BioLinq was last valued at $400M (post-money). It dates from Apr 2025. The company is private, so there is no listed share price.
One company valuation: $400M (post-money), dated Apr 2025.
A private valuation is the price agreed in one transaction. The BioLinq valuation of $400M is a post-money figure.
The valuation holds until the next priced round or secondary sale. A private company founded in 2010 with roughly 118 people has no daily price and no order book between rounds.
The routes section explains what is realistically available for a company at this stage.
No. BioLinq is a private company; its shares do not trade on a public exchange.
The last valuation is $400M (post-money, Apr 2025).
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
